TPT-004

• Description:

  TPT-004 is a selective and oraly active tryptophan hydroxylases (TPH) inhibitor with IC50s of 77 nM and 16 nM for TPH1 and TPH2, repsectively. TPT-004 exhibits exceptional selectivity for TPH1 compared with other members of the AAAH family. TPT-004 shows efficacy peripheral serotonin attenuation and colorectal tumor growth in mice[1][2].

• UNSPSC:

  12352005

• Target:

  Tryptophan Hydroxylase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tpt-004.html

• Purity:

  99.90

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  CCN1C2=C(C(NC1=O)=O)N(C(CC3=CN4C=C(SC4=N3)C)=N2)CC5COC5

• Molecular Formula:

  C18H20N6O3S

• Molecular Weight:

  400.45

• References & Citations:

  [1]Specker E, et al. Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors. J Med Chem. 2023 Oct 31.|[2]Wesolowski R, et al. Selectivity and Safety Characterization of a Xanthine-Imidazothiazole Lead Structure: a Novel Tryptophan Hydroxylase Inhibitor of Peripheral Serotonin Synthesis. ACS Pharmacol Transl Sci. 2025 May 19;8 (6) :1678-1693.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [3032648-15-7]